Sai Life Sciences balance sheet

As of Mar 2026

Total assets: ₹3,626cr+14.8% on Mar 2025
Shareholders' equity: ₹2,484cr+16.7% on Mar 2025
Total debt: ₹95.1cr−26.1% on Mar 2025
Cash and investments: ₹129cr+41.5% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025

Non-current assets
	1,809	1,477
	270	124
	6.1	10.9
	3.5	1.9
	57.8	5.1
	61.3	7.0
	13.4	14.2
	55.6	21.6
	2,216	1,655
Current assets
	151	119
	47.0	0.0
	374	355
	81.9	91.1
	29.0	373
	104	79.6
	635	898
	624	487
	1,411	1,505
	3,626	3,160
Equity
	21.2	20.8
	2,463	2,108
	2,484	2,128
	2,484	2,128
Liabilities
	20.5	0.0
	128	165
	148	165
	32.3	23.4
	128	111
	309	299
	74.6	129
	285	323
	229	135
	589	586
	20.0	10.8
	51.7	8.0
	173	128
	834	732
	1,142	1,032
	3,626	3,160
Trade payables — MSME split
	43.0	47.4
	242	275

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SAILIFE₹1,495.70

Sai Life Sciences Ltd.

· Pharma & Health

₹ CrorePeersSYNGENE DIVISLAB PPLPHARMA NH NEULANDLAB NATCOPHARM LALPATHLAB COHANCEMcap ₹31,676 Cr

View

In ₹ Crore except Per Share As of	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	1,477.4	1,808.7	1,808.7
+ Capital Work-in-Progress	124.5	270.5	270.5
+ Other Intangibles	10.9	6.1	6.1
+ Non-current Investments	1.9	3.5	3.5
+ Other Non-current Financial Assets	5.1	57.8	57.8
Non-current Financial Assets	7.0	61.3	61.3
+ Deferred Tax Assets	14.2	13.4	13.4
+ Other Non-current Assets	21.6	55.6	55.6
Total Non-current Assets	1,655.5	2,215.6	2,215.6
Current Assets
+ Inventories	118.9	151.0	151.0
+ Current Investments	0.0	47.0	47.0
+ Trade Receivables	354.8	373.6	373.6
+ Cash & Cash Equivalents	91.1	81.9	81.9
+ Other Bank Balances	372.8	29.0	29.0
+ Other Current Financial Assets	79.6	104.0	104.0
Current Financial Assets	898.3	635.5	635.5
+ Other Current Assets	487.4	624.1	624.1
Total Current Assets	1,504.5	1,410.5	1,410.5
Total Assets	3,160.0	3,626.1	3,626.1
Equity
+ Equity Share Capital	20.8	21.2	21.2
+ Other Equity / Reserves	2,107.5	2,462.5	2,462.5
Equity — Owners of Parent	2,128.4	2,483.7	2,483.7
Total Equity	2,128.4	2,483.7	2,483.7
Liabilities
+ Borrowings — Non-current	0.0	20.5	20.5
+ Other Non-current Financial Liab	164.7	127.6	127.6
Non-current Financial Liabilities	164.7	148.1	148.1
+ Provisions — Non-current	23.4	32.3	32.3
+ Deferred Tax Liabilities	111.0	128.3	128.3
Non-current Liabilities	299.1	308.8	308.8
+ Borrowings — Current	128.6	74.6	74.6
+ Trade Payables	322.5	285.3	285.3
+ Other Current Financial Liab	134.5	229.4	229.4
Current Financial Liabilities	585.6	589.3	589.3
+ Provisions — Current	10.8	20.0	20.0
+ Current Tax Liabilities	8.0	51.7	51.7
+ Other Current Liabilities	128.1	172.6	172.6
Current Liabilities	732.5	833.7	833.7
Total Liabilities	1,031.6	1,142.5	1,142.5
Total Equity & Liabilities	3,160.0	3,626.1	3,626.1
Trade Payables — MSME split
+ Dues to Micro & Small — Current	47.4	43.0	43.0
+ Dues to Other Creditors — Current	275.1	242.4	242.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.